Anti-neoplastic efficacy of Haimiding on gastric carcinoma and its mechanisms

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 4

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

357

HTML

1840

Figures (1-2)

193

Tables (1-12)

221

Sum=2611

Feb 15, 2004 (publication date) through Oct 3, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Gastric Cancer

World J Gastroenterol. Feb 15, 2004; 10(4): 484-490
Published online Feb 15, 2004. doi: 10.3748/wjg.v10.i4.484

Table 11 Changes of intracellular [Ca²⁺]i in human gastric carcinoma cells after treated with HMD for 48 h

Group	Concentration of drug given (µg/ml)	No.of cells	[Ca²⁺]_i (FI)
A	Same vol. of mediun	22	328.45 ± 135.15
B	50	36	380.42 ± 151.46^b
C₁	200	33	1 119.55 ± 193.94^d
C₂	100	28	787.00 ± 178.19^d
C₃	50	21	547.29 ± 142.25^d
D	100 + 20	26	693.38 ± 168.15^f

^bP < 0.01,

^dP < 0.001 vs negative control;

^fP < 0.01 vs separately medium dose group and negative control group.

Citation: Ji YB, Gao SY, Ji HR, Kong Q, Zhang XJ, Yang BF. Anti-neoplastic efficacy of Haimiding on gastric carcinoma and its mechanisms. World J Gastroenterol 2004; 10(4): 484-490
URL: https://www.wjgnet.com/1007-9327/full/v10/i4/484.htm
DOI: https://dx.doi.org/10.3748/wjg.v10.i4.484